Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Pharmacyclics

    - PMLiVE

    Eli Lilly shares positive results for Jaypirca in head-to-head CLL/SLL study

    Around 23,690 cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    AstraZeneca’s Calquence approved by EC for first-line chronic lymphocytic leukaemia use

    An estimated 27,000 cases of the disease were diagnosed in the UK, France, Germany, Spain and Italy in 2024

    - PMLiVE

    AstraZeneca’s Calquence combination shows promise in chronic lymphocytic leukaemia

    Approximately 4,000 new cases of the disease are diagnosed in the UK every year

    - PMLiVE

    Janssen/Pharmacyclics’ ibrutinib shows continued survival benefit in chronic lymphocytic leukaemia

    The slow-growing blood cancer affects approximately 4.92 per 100,000 people every year in Europe

    - PMLiVE

    Bristol Myers Squibb’s Breyanzi granted FDA accelerated approval for non-Hodgkin lymphomas

    About 20,700 new cases of chronic lymphocytic leukaemia are expected to be diagnosed in the US this year

    - PMLiVE

    Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

    The blood cancer affects approximately 160,000 people worldwide

    - PMLiVE

    FDA grants fast track designation to Nurix’s BTK degrader for non-Hodgkin lymphomas

    CLL is one of the most common types of leukaemia in adults, with around 18,740 new cases in the US last year

    - PMLiVE

    Eli Lilly’s Jaypirca granted FDA accelerated approval for non-Hodgkin lymphomas

    Approximately 18,740 new cases of CLL have been diagnosed in the US this year

    - PMLiVE

    Janssen reveals positive results for nipocalimab in rheumatoid arthritis

    About 13 million people worldwide are affected by the chronic inflammatory disease

    - PMLiVE

    Janssen’s Tecvayli approved by EC for reduced dosing frequency in multiple myeloma

    Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe

    - PMLiVE

    Janssen’s Talvey granted FDA accelerated approval for difficult-to-treat blood cancer

    The therapy showed an overall response rate of more than 70% in a broad range of patients

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links